US Restasis decision is affirmed on appeal
Generic competition to Allergan’s Restasis (cyclosporine) 0.05% ophthalmic solution is looming in the US after a US Court of Appeals affirmed that four key patents are invalid.
Generic competition to Allergan’s Restasis (cyclosporine) 0.05% ophthalmic solution is looming in the US after a US Court of Appeals affirmed that four key patents are invalid.